RESUMO
PURPOSE: The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy. METHODS: We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment. RESULTS: The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p <â0.01). Median progression-free survival (PFS), overall survival (OS) and post-progression survival (PPS) were 3.2 (95% CIâ: 2.63-3.80), 6.5 (95% CIâ: 3.78-9.35) and 2.7 months (95% CIâ: 1.89-3.68), respectively. PFS (râ=â0.55, pâ<â0.01) and PPS (râ=â0.89, pâ<â0.01) were correlated with OS. Response to second-line treatment was independently related to PFS (HRâ: 0.12 95%CIâ: 0.53-0.26, pâ<â0.001). Having an ECOG 0 performance status (HRâ: 0.42â; 95%CIâ: 0.21-0.86, pâ=â0.02) and response to second-line therapy (HRâ: 0.47â; 95%CIâ: 0.25-0.85, pâ=â0.01) were independently associated with OS. CONCLUSION: PPS and PFS were correlated with OS after second-line treatment of MGC. Response to second-line treatment prolonged OS by increasing PFS, and having an ECOG 0 PS prolonged OS by increasing PPS.